TARGETED THERAPIES FOR INFLAMMATORY BOWEL DISEASES AND COLORECTAL CANCER: AN INCREASING NEED FOR MICROBIOTA-INTESTINAL MUTUALISM

The involvement of intestinal microbiota and dysbiosis in the pathogenesis for inflammatory bowel disease (IBD) and colorectal cancer (CRC) is a well-established factto be taken into real consideration when developing targeted therapies. This review aims to depict how advances in our understanding of the role of intestinal flora in the pathogenesis of IBD and CRC are shaping up the therapeutic protocols of their management. It is demonstrated of their management. It is demostrated that there is a circadian regulation of colocyte gene expression in response to microbiota. Dysbiosis leading to a decrease in microbiome biodiversity is also described in IBD patients in IBD patients whereby thic…